BMS Forgoes Thalassemia Label Expansion Revenues For Rebozyl
Withdraws Reblozyl sBLA
Executive Summary
The firm was unable to respond to the US FDA’s questions on Reblozyl’s risk-benefit profile in an expanded beta-thalassemia setting and will now focus label expansion efforts elsewhere.
You may also be interested in...
BMS Broadens Market, De-Risks Long-Term Revenue Potential For Reblozyl
As a first-line treatment for anemia in patients with myelodysplastic syndromes, Reblozyl is approved for indications that will account for 75%-80% of the $4bn-plus in sales Bristol has forecast by 2029.
BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome
The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.
Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker